Bone-Marrow Purging with Monoclonal Antibodies and Human Complement in ALL and AML
Part of the
Haematology and Blood Transfusion / Hämatologie und Bluttransfusion
book series (HAEMATOLOGY, volume 31)
High-dose treatment followed by infusion of histocompatible allogeneic bone marrow has been shown to be curative in many patients with acute leukemia. Inherent in this treatment modality are a number of problems, however. Most prominent among them: graft versus host disease or, when using T cell-depleted marrow, graft failure. In addition, age restriction, conventionally applied to minimize morbidity and mortality, reduces the application of allogeneic bone marrowtransplantation to, on the average, about one third of those with the disease, and of these only about one in three will have a suitable donor.
KeywordsAcute Myeloid Leukemia Acute Leukemia Human Complement Kemic Cell Clonogenic Tumor Cell
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sugita K, Majdic O, Stockinger H, Holter W, Koller U, Peschel C, Knapp W (1986) Int J Cancer 37:351–357PubMedCrossRefGoogle Scholar
Sugita K, Majdic O, Stockinger H, Holter W, Burger R, Knapp W (1987) Transplantation 43:570–574PubMedCrossRefGoogle Scholar
Majdic O, Bettelheim P, Stockinger H, Aberer W, Liszka K, Lutz D, Knapp W (1984) Int J Cancer 33:617–623PubMedCrossRefGoogle Scholar
Peschel C, Konwalinka G, Geissler D, Majdic O, Stockinger H, Braunsteiner H, Knapp W (1985) Exp Hematol 13/11:1211–1216PubMedGoogle Scholar
Delwel R, Touw I, Löwenberg B (1986) In: Hagenbeek A, Löwenberg B (eds) Minimal residual disease in acute leukemia. Nijhoff, Dordrecht, pp 68–75CrossRefGoogle Scholar
Majdic O, Liszka K, Lutz D, Knapp W (1981) Blood 58:1127–1133PubMedGoogle Scholar
Knapp W, Majdic O, Stockinger H, Bettelheim P, Liszka K, Köller U, Peschel C (1984) Med Oncol Tumor Pharmacother 4:257–262Google Scholar
© Springer-Verlag Berlin Heidelberg 1987